Home › Funds › PSP Research LLC › RARE
PSP Research LLC position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
PSP Research LLC reported holding 17,000 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$568K, representing 0.30% of its reported portfolio and ranking #9 among its reported holdings. PSP Research LLC has disclosed RARE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
How PSP Research LLC's RARE position evolved
PSP Research LLC first disclosed a stake in RARE in Q1 2026 at 22,100 shares (US$463K). The position peaked in Q2 2026 at 17,000 shares, worth US$568K. Across 2 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 17,000 shares valued at US$568K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 22.10K | $463.00K | New |
| Q2 2026 | 17.00K | $567.63K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026